Status:
UNKNOWN
Bevacizumab and Combination Chemotherapy in Treating Patients With Previously Untreated Metastatic Colorectal Cancer That Cannot Be Removed By Surgery
Lead Sponsor:
Southern Italy Cooperative Oncology Group
Conditions:
Colorectal Cancer
Eligibility:
All Genders
18-75 years
Phase:
PHASE3
Brief Summary
RATIONALE: Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or...
Detailed Description
OBJECTIVES: Primary * To compare two strategies of induction bio-chemotherapy followed by the same maintenance biotherapy in terms of time to failure in patients with previously untreated metastatic...
Eligibility Criteria
Inclusion
- DISEASE CHARACTERISTICS:
- Histologically or cytologically confirmed colorectal cancer
- Metastatic disease that is not amenable to surgery
- At least one measurable lesion according to RECIST criteria
- No untreated brain metastases or spinal cord compression
- PATIENT CHARACTERISTICS:
- ECOG performance status 0-1
- Life expectancy ≥ 12 weeks
- Hemoglobin ≥ 9.0 g/dL
- ANC ≥ 1,500/mm³
- Platelet count ≥ 100,000/mm³
- Total bilirubin ≤ 1.5 times upper limit of normal (ULN)
- AST and/or ALT ≤ 2.5 times ULN (\< 5 times ULN if liver metastases present)
- Alkaline phosphatase ≤ 2.5 times ULN (\< 5 times ULN if liver metastases present)
- PT-INR/PTT \< 1.5 times ULN
- Creatinine clearance \> 50 mL/min OR serum creatinine ≤ 1.5 times ULN
- Proteinuria on dipstick urinalysis \< 2+ OR 24-hour urine protein ≤ 1g
- Not pregnant or nursing
- Negative pregnancy test
- Must be accessible for treatment and follow-up
- No history of inflammatory bowel disease and/or acute or subacute bowel occlusion
- No serious non-healing wound, ulcer, or bone fracture
- No evidence of bleeding diathesis or coagulopathy
- No uncontrolled hypertension
- No clinically significant cardiovascular disease including any of the following:
- Cerebrovascular accident within the past 6 months
- Myocardial infarction within the past 6 months
- Unstable angina
- New York Heart Association grade II-IV congestive heart failure
- Serious cardiac arrhythmia requiring medication
- No known allergy to Chinese hamster ovary cell proteins or any of the components of the study medications
- No other malignancy within the past 5 years except basal cell and squamous cell skin cancer or carcinoma in situ of the cervix
- No significant traumatic injury within the past 28 days
- No substance abuse or medical, psychological, or social conditions that may interfere with participation in the study or the evaluation of study results
- Able to swallow oral medications
- PRIOR CONCURRENT THERAPY:
- See Disease Characteristics
- At least 6 months since prior adjuvant treatment
- No prior irinotecan and/or bevacizumab during prior adjuvant therapy
- No prior cytotoxic drugs for the metastatic disease
- More than 10 days since prior and no concurrent anticoagulants for therapeutic purposes
- No chronic, daily treatment with high-dose aspirin (\> 325 mg/day) or other medications known to predispose to gastrointestinal ulceration
- No treatment with any investigational drug within the past 30 days
- No major surgical procedure or open biopsy within the past 28 days or anticipated need for a major surgical procedure during the course of the study
Exclusion
Key Trial Info
Start Date :
July 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
Estimated Enrollment :
672 Patients enrolled
Trial Details
Trial ID
NCT00797485
Start Date
July 1 2008
Last Update
August 26 2013
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Southern Italy Cooperative Oncology Group
Naples, Italy, 80131